Pharmaceuticals
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
* Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets, Strengthening Collaboration with Distribution Partner McKesson * Introducing 'Countmate': A Customized Solution for Canadian and American Pharmacists Seeking Advanced Vial Preparation Techn...
2025-02-14 08:35
2448
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patien...
2025-02-13 18:53
1738
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the ...
2025-02-13 13:40
1716
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bis...
2025-02-13 09:26
2007
Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the publication of its most recent peer-reviewed...
2025-02-12 21:00
2208
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced that the U.S. Food and Drug Administration (...
2025-02-12 21:00
2019
Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management - Recognition reflects Samsung Biologics' commitment to water security and implementing sustainable practices across operations INCHEON, South Korea, Feb. 12, 2025 /PRNewswire/ -- Samsung Biolo...
2025-02-12 20:00
2627
111, Inc. Regains Compliance with NASDAQ Requirement
SHANGHAI, Feb. 11, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced today that it has recei...
2025-02-11 21:00
2398
GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025
YONGIN, South Korea , Feb. 11, 2025 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced onFeb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held fromFeb. 3rd to 7th, 2025, in San Diego, USA....
2025-02-11 16:40
1993
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
* Ranked among the top 1% of companies assessed in the pharmaceutical industry * Recognized as a leader in Green CRDMO, driving innovation for a healthier future * Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
2025-02-10 17:00
2661
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 f...
2025-02-10 15:32
2236
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
* CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase2b study (CBL-0205) before Phase 3. * 54.2% of participants in the CBL-514 group achieved at least 20% fat volume reduction four week...
2025-02-10 14:15
2260
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
SUZHOU, China, Feb. 9, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly® (sugemalimab), has been included in the Europe...
2025-02-10 12:20
2404
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Ka...
2025-02-08 09:14
5106
Argent BioPharma: A Hidden Gem traded Under $12M--Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment
PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective trea...
2025-02-06 05:00
2556
Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem
Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xaname...
2025-02-05 22:18
2913
I Peace establishes and offers low immunoreaction risk GMP iPS Cells
Three lines of GMP iPS Cells derived from type O female blood are now offered
as off-the-shelf product
PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://ipeace.com/en/
2025-02-05 22:00
2515
From 0 to 100 Trillion: The Rise of Sanyou Bio's Intelligent Molecule Library
SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a deca...
2025-02-05 18:00
2147
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the l...
2025-02-05 13:00
2558
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunol...
2025-02-05 12:28
2568
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6681
